METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF TICARGRELOR IN BULK AND COMPARISON WITH OTHER PUBLISHED METHODS
Abstract
The following article consist of highly sensitive and easy RP-HPLC method to estimate Ticagrelor in bulk. Ticagrelor was separated using Shimadzu LC-20-AD with auto sampler and PDA/UV detector. The separation was achieved using a C18 Vydac Monomeric 120A (5.0 micron, 250 x 4.6mm) column. Acetonitrile: Water Milli Q (60:40 v/v) at a flow rate of 1.0 ml/min was used as the mobile phase. The method was linear having line equation f(x)=1.90442e-005*x-0.302059 with correlation coefficient (R2) of 0.997. The method was precise having RSD as 0.27% (intraday precision). The LOD & LOQ were 0.083μg/mL and 0.25μg/mL respectively. The developed method was validated for precision, linearity, system suitability and robustness; hence proves that it is highly applicable to estimate Ticagrelor in day to day analysis.
Full Text:
PDFReferences
Khaleel A, Rohit S, Ambrish S, Kashyap P, Anad S, Ticagrelor: a new reversible oral antiplatelet agent. International Research Journal of Pharmacy. 2010;1:62-69.
Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology. 2010;66(5):487-496.
Husted Svan Giezen J. Ticagrelor: The First Reversibly Binding Oral P2Y 12 Receptor Antagonist. Cardiovascular Therapeutics. 2009;27(4):259-274.
Wallentin L, Becker R, Budaj A, Cannon C, Held C. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2009;11:1045-1057.
Teng R, Oliver S, Hayes M, Butler K. Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects. Drug Metabolism and Disposition. 2010;38(9):1514-1521.
Ticagrelor for the treatment of acute coronary syndromes. TA236. October 2011. Prescriber. 2011;22(22):18-18.
Nawarskas J, Clark S. Ticagrelor. Cardiology in Review. 2011;19(2):95-100.
Deeks E. Ticagrelor. Drugs. 2011;71(7):909-933.
Ambasana M, Kapuriya N, Faldu N, Ladva K. Development and validation of a UV spectrophotometric method for the determination of ticagrelor in bulk form. Der Pharmacia Letters. 2014;4:237-240.
Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. Journal of Chromatography B. 2010;878(25):2299-2306.
Sillén H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC–MS/MS. Journal of Chromatography B. 2011;879(23):2315-2322.
Kalyani LRao Lakshmana A. A Validated StabilityIndicating Hplc Method For Determination of Ticagrelor in Bulk and Its Formulation. International journal of Pharmacy. 2013;3:634-642.
Gobetti C, Pereira R, Mendez A, Garcia C. Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method. CPA. 2014;10(4):279-283.
An Improved Assay Method for the estimation of Ticagrelor Hydrochloride by reverse phase liquid chromatography". International journal of pharmaceutical sciences and Research. 2016;7:0975-8232.
Refbacks
- There are currently no refbacks.
